Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Accumulated Expenses (2017 - 2025)

Abeona Therapeutics has reported Accumulated Expenses over the past 13 years, most recently at $5.6 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $5.6 million for Q4 2025, down 11.01% from a year ago — trailing twelve months through Dec 2025 was $5.6 million (down 11.01% YoY), and the annual figure for FY2025 was $5.6 million, down 11.01%.
  • Accumulated Expenses for Q4 2025 was $5.6 million at Abeona Therapeutics, down from $6.9 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ABEO hit a ceiling of $6.9 million in Q3 2025 and a floor of $745000.0 in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $3.1 million (2021), compared with a mean of $3.5 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 74.02% in 2022 and later surged 244.83% in 2023.
  • Abeona Therapeutics' Accumulated Expenses stood at $5.6 million in 2021, then plummeted by 53.57% to $2.6 million in 2022, then surged by 42.23% to $3.7 million in 2023, then surged by 71.72% to $6.3 million in 2024, then decreased by 11.01% to $5.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $5.6 million (Q4 2025), $6.9 million (Q3 2025), and $5.5 million (Q2 2025) per Business Quant data.